title: Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy.
authors.forename: Victoria
authors.initials: V
authors.lastname: Ling
authors.forename: Alan K
authors.initials: AK
authors.lastname: Burnett
authors.forename: Ken
authors.initials: K
authors.lastname: Bradstock
authors.forename: John F
authors.initials: JF
authors.lastname: Seymour
authors.forename: Robert K
authors.initials: RK
authors.lastname: Hills
authors.forename: Andrew
authors.initials: A
authors.lastname: Wei
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015331:Cohort Studies; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D003561:Cytarabine